On 28 May, the RIVM published a report on the current state of knowledge about bacteriophages. The RIVM study was commissioned by the Ministry of Health, Welfare and Sport after publications in the media about phage therapy. Since the television broadcast Dokters van Morgen, microbiologist Marc Bonten of the UMC Utrecht is regularly confronted with patients who demand treatment with bacteriophages. “I receive weekly mails from patients who request it, and in one case someone has also demanded such treatment.”
In February of this year, UMC Utrecht (in collaboration with TU Delft and the Netherlands Center for One Health) organized an international symposium for the first time in the Netherlands. The main subject was the possibility of phage therapy in the treatment of patients with infections caused by bacteria resistant to antibiotics. Experts from home and abroad presented their experiences in research and therapy in relation to bacteriophages in Utrecht.
UMC Utrecht has started a biobank with bacteriophages with which research is being performed. These studies form the preliminary work of patient-related research for which UMC Utrecht is currently preparing.
In theory, bacteriophages seem to be a good way to combat infections caused by bacteria that are insensitive to the effects of antibiotics. “However, there is still insufficiently clinical evidence available,” the RIVM researchers write, “to know the added value of bacteriophage treatment and to be able to do this safely and for multiple types of infections.”
Marc Bonten is now working with colleagues to set up a clinical trial in which patients will be treated with bacteriophages. However, whether the study can be executed is not certain. “It is still very exciting whether we get permission,” he says. The permit for the research must come from the Central Committee on Human Research (CCMO). “Phage therapy is not authorized medicines, so we can not just use them,” says Bonten. “We are now having the Queen Astrid Hospital in Brussels prepare the phages for the bacterial strains of our patients in their pharmacy, and we’ll get them to the Netherlands, hopefully this will be allowed by the CCMO.” In Belgium this preparation of phages has been approved after four years of debate.”
The Netherlands Centre for One Health (NCOH) was allocated a budget of two million euro Public-Private Partnership (PPP) Allowance to organise and realise their first PPP call. This call involves strategic partnerships under the Knowledge and Innovation Agenda of Top Sector Life Sciences & Health (LSH): One Health call.
The number of bacteria that are resistant to antibiotics is increasing globally. In the Netherlands this number remains fairly stable and is lower than in many other countries. Nevertheless, there is still cause for concern and caution. This is evident from the annual report NethMap/MARAN 2019 in which various organisations jointly present data on antibiotic...
A malaria vaccine, based on genetically-manipulated malaria parasites. That is the goal of Meta Roestenberg (LUMC) and Robert Sauerwein (Radboudumc). More than ten years of collaboration is nearing completion. But the vaccine could be even better…
The second edition of the NCOH Magazine has been published at the Annual Scientific Meeting at Radboudumc 17 may. Here is your chance to look at the digital version.